Sunshine Biopharma Inc. (SBFM) – What You Need to Know

Thinking about investing in Sunshine Biopharma? You might have heard they are launching an "IPO." However, they already trade on the NASDAQ under the ticker SBFM. They are actually running a new fundraising campaign to raise up to $6 million. Let’s break down what they do, how they make money, and what you should know before buying.

1. What does this company actually do?

Sunshine Biopharma runs three different businesses:

• The Cash Generator (Generic Drugs): Their subsidiary, Nora Pharma, sells 60 generic prescription drugs in Canada. This main business brings in steady sales by offering cheaper alternatives to brand-name drugs.
• The Everyday Side (Supplements): They sell over-the-counter supplements, mainly Essential 9, an amino acid blend for general health.
• The Lab (Experimental Drugs): They are developing an mRNA liver cancer drug and a COVID-19 antiviral. Both are in early lab testing and have not been tested on humans yet. The company hasn't provided a detailed timeline for human trials in their filing, which is common for drugs in such early stages.

2. How do they make money?

Unlike many young biotech firms, Sunshine Biopharma actually makes money. They bring in steady sales from generic drugs and supplements.

However, they are not profitable yet. Developing new drugs is incredibly expensive. Because of this, the company has a lifetime loss of over $75 million. They spend cash quickly on research and administrative costs, far outstripping their current sales.

3. What are the details of this stock sale?

The company is selling "units" to raise up to $6 million in total. After paying fees, they will keep about $5 million to run the business.

• The Price: They plan to sell each unit for about $1.03.
• What is a "Unit"? Each unit includes one regular share and two "Series C Warrants." A warrant lets the holder buy more regular shares later for $1.03. These warrants won't trade on any exchange, making them very hard to sell.
• More Shares Issued, Reducing Your Ownership: The company has about 5 million regular shares today. This sale will push that total to over 10.8 million shares. Doubling the share count immediately cuts your ownership percentage and voting power in half.

4. What are the main risks?

• The CEO Controls Everything: Regular investors get one vote per share. However, the CEO, Dr. Steve Slilaty, holds special voting shares. These give him 1,000 votes per share, totaling 130 million votes. He has absolute control over all decisions, leaving you with zero say.
• The 15-Million-Share Time Bomb: Investors from past deals hold 15.2 million older warrants (Series B). Because this new sale is priced low at $1.03, a special clause triggers. This automatically lowers the price of those older warrants and lets holders claim millions of new shares. This could flood the market and crash the stock price.
• The "Kicked Off the Exchange" Risk: SBFM must keep its stock price above $1.00 to stay on the Nasdaq. It has been trading dangerously close to this limit. If it drops below $1.00 for too long, Nasdaq will delist it, making the stock much harder to sell.
• The Reverse-Split Trap: The company might combine shares to boost the stock price and avoid delisting. However, if they do this and the price falls again, the new Series C warrants can reset their price down to $0.53. This lets warrant holders buy shares at a steep discount, further reducing your ownership percentage.
• A Habit of Asking for Cash: The company constantly issues more shares to survive. Their investment bank, Aegis Capital Corp., has run six fundraising campaigns since 2022. These deals are expensive. Aegis has charged up to 10% in fees, and this current deal costs over $300,000 in fees alone.

The Bottom Line

Sunshine Biopharma has a real business. Selling 60 generic drugs brings in actual money, setting them apart from other young biotech firms. Still, they spend cash fast and have a lifetime loss of over $75 million.

For retail investors, the risks are massive. The CEO has total control, and this new sale immediately cuts your ownership in half. Plus, complex warrant rules threaten to flood the market with cheap shares. This makes SBFM a highly speculative, high-risk investment.